David A. Nathanson
APLA Health(US)University of California, Los Angeles(US)
Publications by Year
Research Areas
Glioma Diagnosis and Treatment, RNA modifications and cancer, Immunotherapy and Immune Responses, Histone Deacetylase Inhibitors Research, Cancer Research and Treatments
Most-Cited Works
- → Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions(2020)1,083 cited
- → Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity(2017)869 cited
- → Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA(2013)673 cited
- → An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway(2011)442 cited
- → Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance(2011)278 cited
- → Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma(2021)250 cited
- → 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling(2015)238 cited
- → EGFR Mutation-Induced Alternative Splicing of Max Contributes to Growth of Glycolytic Tumors in Brain Cancer(2013)163 cited
- → CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis(2023)162 cited
- → De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients(2013)141 cited